The evidence for pulmonary rehabilitation (PR) as a non-pharmacological management strategy for people with idiopathic pulmonary fibrosis (IPF) is consistent and continues to accrue. Meta-analysis has demonstrated that it effectively improves exercise capacity, dyspnoea and health-related quality of life,1 and preliminary data suggest that improved physical performance following PR is associated with improved survival.2 However, these benefits are short-lived, lasting no more than 6 months.1 Despite this, no study has investigated strategies to maintain the benefits of PR in IPF, although two have been undertaken in interstitial lung disease (ILD) and demonstrated maintenance of benefit at 6 and 12 months post-PR.3 4 The development of pharmacotherapy was a watershed moment in the management of IPF and is now part of standard treatment for select individuals. In particular, nintedanib slows the decline in measures of disease severity5 and it is hypothesised that there may be a cumulative benefit on exercise capacity by combining nintedanib and exercise. However, due to the relatively recent availability of this therapy, there are limited data, with retrospective analyses reporting conflicting results on the short-term effect of antifibrotic therapies plus PR on exercise capacity.6 7 In this edition of Thorax , Kataoka et al report the results of a multicentre randomised controlled trial undertaken in Japan that compared the effect of PR plus a maintenance programme to usual care (no intervention) on 6 min …

中文翻译：

---

特发性肺纤维化肺康复后的维持计划：运动、药物和摇滚


肺康复（PR）作为特发性肺纤维化（IPF）患者的非药物治疗策略的证据是一致的，并且还在不断增加。荟萃分析表明，它可以有效改善运动能力、呼吸困难和健康相关的生活质量，1并且初步数据表明，PR 后身体机能的改善与生存率的提高相关。2 然而，这些益处是短暂的、不持久的。超过 6 个月。1 尽管如此，尚无研究调查在 IPF 中维持 PR 益处的策略，尽管两项研究已在间质性肺疾病 (ILD) 中进行，并证明在 PR 后 6 个月和 12 个月仍能维持益处。3 4 药物疗法的发展是 IPF 治疗的分水岭，现在已成为特定个体标准治疗的一部分。特别是，尼达尼布可以减缓疾病严重程度指标的下降5，并且假设尼达尼布和运动相结合可能会对运动能力产生累积益处。然而，由于这种疗法相对较新才出现，数据有限，回顾性分析报告了抗纤维化疗法加 PR 对运动能力的短期效果相互矛盾的结果。6 7 在本期 Thorax 中，Kataoka 等人报告日本进行的一项多中心随机对照试验的结果，该试验比较了 PR 加维持计划与常规护理（无干预）6 分钟的效果……